Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prophylaxis of visceral leishmaniasis. The vaccine, identified as LEISH-F3 + GLA-SE, consists of the recombinant two-antigen Leishmania recombinant protein LEISH-F3 together with the adjuvant GLA-SE.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Leishmaniasis

Clinical Trial Details

NCT number	NCT01484548
Study type	Interventional
Source	IDRI
Contact
Status	Completed
Phase	Phase 1
Start date	January 2012
Completion date	May 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03641339` - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans	N/A
Completed	`NCT04504435` - Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants	Phase 1
Completed	`NCT00004755` - Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil	Phase 2
Completed	`NCT00657618` - Use of Sodium Stibogluconate as a Treatment for Leishmaniasis	Phase 1/Phase 2
Completed	`NCT04512742` - A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies	N/A
Recruiting	`NCT00344188` - Diagnosis and Treatment of Leishmania Infections
Active, not recruiting	`NCT03009422` - Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.	N/A
Recruiting	`NCT05449717` - Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
Recruiting	`NCT06307171` - Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers	N/A
Completed	`NCT01751048` - LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine	Phase 1
Terminated	`NCT06124144` - Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults	Phase 1
Completed	`NCT00662012` - Sodium Stibogluconate Treatment of Leishmaniasis	Phase 2
Completed	`NCT03993093` - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Recruiting	`NCT03784248` - Mediterranean Visceral Leishmaniasis With Leishmania Infantum
Withdrawn	`NCT02429505` - Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
Completed	`NCT01377974` - Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis	Phase 2
Completed	`NCT02656797` - Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis	Phase 2
Completed	`NCT01300975` - Intralesional Antimony for Bolivian Cutaneous Leishmaniasis	Phase 2
Completed	`NCT03294161` - Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis	Phase 2
Completed	`NCT00401297` - Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes